CERS Pengajuan SEC - Cerus Corporation- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	254900BIEY9XIDA04Q21
CIK	1020214

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cerus Corporation

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 5, 2025	S-8	As filed with the Securities and Exchange Commission on August 5, 2025 S-8 As filed with the Securities and Exchange Commission on August 5, 2025 Registration No.
August 5, 2025	EX-10.2	Cerus Corporation Amended and Restated 2024 Equity Incentive Plan Exhibit 10.2 CERUS CORPORATION 2024 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS ON: MARCH 29, 2024 APPROVED BY THE STOCKHOLDERS ON: JUNE 5, 2024 amended and restated by the board of directors on: March 28, 2025 approved by the stockholders on: june 3, 2025 1. General. (a) Successor to and Continuation of 2008 Plan. The Plan is intended as the successor to and continuation of the Cerus
August 5, 2025	8-K	FORM 8-K Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2025 CERUS CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File
August 5, 2025	EX-99.1	Cerus Corporation Announces Second Quarter 2025 Financial Results Second Quarter Total Revenue of $60.1 Million; Record Product Revenue of $52.4 Million, Up 16% Year-Over-Year Raising Full-Year 2025 Product Revenue Guidance Range to $200 Million - $2 Exhibit 99.1 Cerus Corporation Announces Second Quarter 2025 Financial Results Second Quarter Total Revenue of $60.1 Million; Record Product Revenue of $52.4 Million, Up 16% Year-Over-Year Raising Full-Year 2025 Product Revenue Guidance Range to $200 Million - $203 Million Conference Call Today at 4:30 pm ET CONCORD, CA, August 5, 2025- Cerus Corporation (Nasdaq:CERS) announced financial results f
August 5, 2025	EX-FILING FEES	Filing Fee Table. Calculation of Filing Fee Tables S-8 CERUS CORP Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Amended and Restated 2024 Equity Incentive Plan Common Stock, par value $0.
August 5, 2025	EX-10.1	Amendment #2 to Supply Agreement, by and between Cerus Corporation and Purolite Corporation, effective January 1, 2025. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [ * ], HAS BEEN OMITTED BECAUSE CERUS CORPORATION HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CERUS CORPORATION IF PUBLICLY DISCLOSED.
August 5, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CERUS CORP
June 23, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2025 CERUS CORPORATION (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2025 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
June 9, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 Cerus Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Num
May 30, 2025	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Cerus Corporation (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Cerus Corporation (Exact name of registrant as specified in its charter) Delaware 000-21937 (State or other jurisdiction of incorporation) (Commission file number) 1220 Concord Ave, Suite 600 Concord, California 94520 (Address of principal executive offices) (Zip Code) Chrystal N. Jensen C
May 23, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant  Filed by a party other than the Registrant  Check the appropriate box:  Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  Defini
May 1, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CERUS COR
May 1, 2025	EX-10.1	Director Compensation Policy, dated April 23, 2025 Exhibit 10.1 Cerus Corporation Amended and Restated Non-Employee Director Compensation Policy Effective: January 1, 2012 Amended by Compensation Committee: February 13, 2014 Approved by Board of Directors: February 14, 2014 Amended by Board of Directors: April 19, 2017 Amended by Board of Directors: March 2, 2018 Amended by Board of Directors: March 27, 2020 Amended by Board of Directors: February
May 1, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 01, 2025 CERUS CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Num
May 1, 2025	EX-99.1	Cerus Corporation Announces First Quarter 2025 Financial Results First quarter 2025 Product Revenue of $43.2 Million, Up 13% Over Prior Year Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 - $200 Million First Quarter 2025 Total Rev Exhibit 99.1 Cerus Corporation Announces First Quarter 2025 Financial Results First quarter 2025 Product Revenue of $43.2 Million, Up 13% Over Prior Year Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 - $200 Million First Quarter 2025 Total Revenue of $48.9 Million Including Government Contract Revenue of $5.6 Million Conference Call Today at 4:30 pm ET CONCORD, CA, May 1, 2025
April 23, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 23, 2025	DEF 14A	QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING PROPOSAL NO. 1 ELECTION OF DIRECTORS INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS PROPOSAL NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
February 26, 2025	EX-21.1	List of Registrant’s subsidiaries. Exhibit 21.1 Cerus Corporation Subsidiaries of the Registrant Legal Name Jurisdiction of Formation Cerus Europe B.V Netherlands
February 26, 2025	EX-97.1	Incentive Compensation Recoupment Policy. Exhibit 97.1 Cerus Corporation Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Cerus Corporation, a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recoverable Ince
February 26, 2025	EX-10.47	License Agreement, dated as of February 2, 2005, by and between Cerus Corporation and Fresenius Kabi AG (successor-in-interest to Baxter Healthcare S.A. and Baxter Healthcare Corporation). CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [ * ], HAS BEEN OMITTED BECAUSE CERUS CORPORATION HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CERUS CORPORATION IF PUBLICLY DISCLOSED.
February 26, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-21937 CERUS CORPORATION (Exact n
February 26, 2025	EX-19.1	Cerus Corporation Insider Trading Policy. Exhibit 19.1 Cerus Corporation Insider Trading Policy (adopted March 29, 2024) Introduction During the course of your relationship with Cerus Corporation (“Cerus”), you may receive material information that is not yet publicly available (“material nonpublic information”) about Cerus or other publicly traded companies. Material nonpublic information may give you, or someone you pass that informatio
February 26, 2025	EX-10.3	Second Amended and Restated Supply and Manufacturing Agreement, dated December 9, 2024, by and between Cerus Corporation and Porex Corporation. [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.
February 20, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 CERUS CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission Fil
February 20, 2025	EX-99.1	Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results Full-Year and Fourth Quarter 2024 Product Revenues Increased 15% and 9%, respectively from Prior Year Periods Fourth straight quarter of positive operating cash flows Rei Exhibit 99.1 Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results Full-Year and Fourth Quarter 2024 Product Revenues Increased 15% and 9%, respectively from Prior Year Periods Fourth straight quarter of positive operating cash flows Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 – $200 million CONCORD, CA, February 20, 2025 - Cerus Corporation (Nasdaq:
February 6, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 02, 2025 CERUS CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission Fil
January 13, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 CERUS CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File
January 13, 2025	EX-99.1	Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update Preliminary Full-Year 2024 Product Revenues Total $180.3 million, 15% Over 2023 Results and Exceed Prior Product Revenue Guidance 2 Exhibit 99.1 Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update Preliminary Full-Year 2024 Product Revenues Total $180.3 million, 15% Over 2023 Results and Exceed Prior Product Revenue Guidance 2025 Product Revenues Expected to be Between $194-$200 million, Reflecting 8%-11% Growth Year-Over-Year January 13, 2025, CONCORD, Calif.—
December 9, 2024	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 09, 2024 CERUS CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission Fil
November 12, 2024	SC 13G/A	CERS / Cerus Corporation / ARK Investment Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm2427988d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7)* CERUS CORPORATION (Name of Issuer) Common stock (Title of Class of Securities) 157085101 (CUSIP Number) October 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat
October 31, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CERUS
October 30, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 CERUS CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File
October 30, 2024	EX-99.1	Cerus Corporation Announces Third Quarter 2024 Financial Results Third Quarter and First Nine-Month Product Revenue Increased 16% and 18%, respectively from Prior Year Periods Raising Full-Year 2024 Total Product Revenue Guidance to the Range of $177 Exhibit 99.1 Cerus Corporation Announces Third Quarter 2024 Financial Results Third Quarter and First Nine-Month Product Revenue Increased 16% and 18%, respectively from Prior Year Periods Raising Full-Year 2024 Total Product Revenue Guidance to the Range of $177 million to $179 million and INTERCEPT Fibrinogen Complex Revenue Guidance to a range of $9 to $10 million CONCORD, CA, October 30, 2024
October 16, 2024	EX-99.1	Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe Company to Host Conference Call and Webcast on Wednesday, October 16, 2024 at 5:00 p.m. EDT Exhibit 99.1 Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe Company to Host Conference Call and Webcast on Wednesday, October 16, 2024 at 5:00 p.m. EDT CONCORD, CA, October 16, 2024 - Cerus Corporation (Nasdaq:CERS) today announced updates on the INTERCEPT red blood cell (RBC) programs in the U.S. and in Europe: • U.S. – New $248 million BARDA contra
October 16, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2024 Cerus Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File
August 1, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CERUS CORP
August 1, 2024	EX-10.4	Form of Restricted Stock Unit Agreement for Non-Employee Directors under the 2024 Equity Incentive Plan. Non-Employee Director Form Exhibit 10.4 Cerus Corporation 2024 Equity Incentive Plan Restricted Stock Unit Agreement Pursuant to the Restricted Stock Unit Grant Notice (“Grant Notice”) and this Restricted Stock Unit Agreement (“Agreement”) (collectively, the “Award”), Cerus Corporation (the “Company”) has awarded you, pursuant to its 2024 Equity Incentive Plan (the “Plan”), the number of Restricte
August 1, 2024	EX-10.2	Amended and Restated 1996 Employee Stock Purchase Plan. Exhibit 10.2 CERUS CORPORATION AMENDED AND RESTATED EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. (a) The purpose of the Employee Stock Purchase Plan (the “Plan”) is to provide a means by which employees of Cerus Corporation, a California corporation (the “Company”), and its Affiliates, as defined in subparagraph 1(b), which are designated as provided in subparagraph 2(b), may be given an opportunity t
August 1, 2024	EX-10.3	Amended and Restated Non-Employee Director Compensation Policy, effective June 4, 2024. Exhibit 10.3 Cerus Corporation Amended and Restated Non-Employee Director Compensation Policy Effective: January 1, 2012 Amended by Compensation Committee: February 13, 2014 Approved by Board of Directors: February 14, 2014 Amended by Board of Directors: April 19, 2017 Amended by Board of Directors: March 2, 2018 Amended by Board of Directors: March 27, 2020 Amended by Board of Directors: February
August 1, 2024	EX-10.1	Cerus Corporation 2024 Equity Incentive Plan. Exhibit 10.1 Cerus Corporation 2024 Equity Incentive Plan APPROVED BY THE BOARD OF DIRECTORS ON: MARCH 29, 2024 APPROVED BY STOCKHOLDERS ON: JUNE 5, 2024 1. General. (a) Successor to and Continuation of 2008 Plan. The Plan is intended as the successor to and continuation of the Cerus Corporation Amended and Restated 2008 Equity Incentive Plan (the “2008 Plan”). Following the Effective Date, no add
August 1, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2024 CERUS CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File
August 1, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Cerus Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity 2024 Equity Incentive Plan Common Stock, par value $0.
August 1, 2024	EX-99.1	Cerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range First Half of 2024 Product Revenue Increased 20% from Prior Year Period Increasing Full-Year 2024 Product Revenue Guidance R Exhibit 99.1 Cerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range First Half of 2024 Product Revenue Increased 20% from Prior Year Period Increasing Full-Year 2024 Product Revenue Guidance Range from $172-175 Million to $175-178 Million CONCORD, CA, August 1, 2024 - Cerus Corporation (Nasdaq: CERS) today announced financial r
August 1, 2024	S-8	As filed with the Securities and Exchange Commission on August 1, 2024 As filed with the Securities and Exchange Commission on August 1, 2024 Registration No.
July 2, 2024	EX-99.1	Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors Exhibit 99.1 Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors CONCORD, CA, July 2, 2024 - Cerus Corporation (Nasdaq: CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development,
July 2, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 01, 2024 CERUS CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Nu
June 11, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2024 CERUS CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Nu
May 31, 2024	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Cerus Corporation (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Cerus Corporation (Exact name of registrant as specified in its charter) Delaware 000-21937 (State or other jurisdiction of incorporation) (Commission file number) 1220 Concord Ave, Suite 600 Concord, California 94520 (Address of principal executive offices) (Zip Code) Chrystal N. Jensen C
May 2, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 02, 2024 CERUS CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Num
May 2, 2024	EX-99.1	Cerus Corporation Announces First Quarter 2024 Financial Results First Quarter Product Revenue Increased 24% from Prior Year Quarter Exhibit 99.1 Cerus Corporation Announces First Quarter 2024 Financial Results First Quarter Product Revenue Increased 24% from Prior Year Quarter CONCORD, CA, May 2, 2024 - Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2024. Recent highlights include: • First-quarter 2024 total revenue was comprised of (in thousands, except %): Three Mon
May 2, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CERUS COR
April 26, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 26, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 19, 2024	EX-99.1	Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients Trial met the primary efficacy endpoint demonstrating non-inferiority of the inci Exhibit 99.1 Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients Trial met the primary efficacy endpoint demonstrating non-inferiority of the incidence of acute kidney injury for INTERCEPT Red Blood Cells compared to conventional red blood cells CONCORD, CA, March 19, 2024 - Cerus C
March 19, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 CERUS CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File N
March 5, 2024	EX-4.2	Description of securities registered under Section 12 of the Exchange Act of 1934. Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK Our amended and restated certificate of incorporation, as amended, or the Restated Certificate, authorizes us to issue 400,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. The following summary description of our capital stock is based on the provisions of the Restated Certifica
March 5, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 05, 2024 CERUS CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File N
March 5, 2024	EX-10.1	Amended and Restated Supply Agreement, dated April 21, 2014, by and between Cerus Corporation and Purolite Corporation. Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [ * ], HAS BEEN OMITTED BECAUSE CERUS CORPORATION HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CERUS CORPORATION IF PUBLICLY DISCLOSED. AMENDED AND RESTATED SUPPLY AGREEMENT THIS AMENDED AND RESTATED SUPPLY AGREEMENT (THE “SUPPLY AGREEMENT”) is made effective as
March 5, 2024	EX-10.3	Amended and Restated Supply and Manufacturing Agreement, dated April 1, 2017, by and between Cerus Corporation and Porex Corporation. Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [ * ], HAS BEEN OMITTED BECAUSE CERUS CORPORATION HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CERUS CORPORATION IF PUBLICLY DISCLOSED. SUPPLY AND MANUFACTURING AGREEMENT This Amended and Restated Supply and Manufacturing Agreement (the “Supply Agreement”) is ma
March 5, 2024	EX-10.9	Amendment No. 1 to Amended and Restated Credit, Security and Guaranty Agreement (Term Loan), dated September 1, 2023, by and among Cerus Corporation, the lenders party thereto and MidCap Financial Trust. Exhibit 10.9 Execution Version CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [ * ], HAS BEEN OMITTED BECAUSE CERUS CORPORATION HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CERUS CORPORATION IF PUBLICLY DISCLOSED. AMENDMENT NO. 1 TO AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) This AMENDMENT N
March 5, 2024	EX-99.1	Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results Sequential Revenue Growth in the Fourth Quarter Driven by Sales in North America Narrowed GAAP Net Loss Attributable to Cerus Corporation to $1.3 Million for the Fourth Q Exhibit 99.1 Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results Sequential Revenue Growth in the Fourth Quarter Driven by Sales in North America Narrowed GAAP Net Loss Attributable to Cerus Corporation to $1.3 Million for the Fourth Quarter and Achieved Goal of Adjusted EBITDA Breakeven for the Fourth Quarter Reiterating Full-Year 2024 Product Revenue Guidance Range of
March 5, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-21937 CERUS CORPORATION (Exact n
March 5, 2024	EX-10.6	Amended and Restated Supply Agreement, dated as of September 1, 2011, between Cerus Corporation and Ash Stevens Inc. Exhibit 10.6 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [ * ], HAS BEEN OMITTED BECAUSE CERUS CORPORATION HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CERUS CORPORATION IF PUBLICLY DISCLOSED. SUPPLY AGREEMENT AMENDED AND RESTATED BETWEEN ASH STEVENS INC. AND CERUS CORPORATION TABLE OF CONTENTS SEC. PAGE 1. PURCHASES
March 5, 2024	EX-21.1	List of Registrant’s subsidiaries. Exhibit 21.1 Cerus Corporation Subsidiaries of the Registrant Legal Name Jurisdiction of Formation Cerus Europe B.V Netherlands
March 5, 2024	EX-10.10	Amendment No. 2 to Amended and Restated Credit, Security and Guaranty Agreement (Term Loan), dated January 5, 2024, by and among Cerus Corporation, the lenders party thereto and MidCap Financial Trust. Exhibit 10.10 Execution Version CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE CERUS CORPORATION HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CERUS CORPORATION IF PUBLICLY DISCLOSED. amendment No. 2 to AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) This AMENDMENT
March 5, 2024	EX-10.12	Amendment No. 1 to Amended and Restated Credit, Security and Guaranty Agreement (Revolving Loan), dated January 5, 2024, by and among Cerus Corporation, the lenders party thereto and MidCap Financial IV Trust. Exhibit 10.12 Execution Version CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE CERUS CORPORATION HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CERUS CORPORATION IF PUBLICLY DISCLOSED. AMENDMENT NO. 1 TO AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN) This AMEND
March 5, 2024	EX-10.4	First Amendment to Supply and Manufacturing Agreement, by and between Cerus Corporation and Porex Corporation, dated June 22, 2018. Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [ * ], HAS BEEN OMITTED BECAUSE CERUS CORPORATION HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CERUS CORPORATION IF PUBLICLY DISCLOSED. FIRST AMENDMENT TO SUPPLY AND MANUFACTURING AGREEMENT This First Amendment (“Amendment”) to the Supply and Manufacturing Agree
February 14, 2024	SC 13G/A	CERS / Cerus Corporation / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.
February 13, 2024	SC 13G/A	CERS / Cerus Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0576-ceruscorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Cerus Corp Title of Class of Securities: Common Stock CUSIP Number: 157085101 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursu
January 29, 2024	SC 13G/A	CERS / Cerus Corporation / ARK Investment Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm244117d14sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6)* CERUS CORPORATION (Name of Issuer) Common stock (Title of Class of Securities) 157085101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa
January 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 08, 2024 CERUS CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File
January 8, 2024	EX-99.1	Cerus Corporation Announces Preliminary Fourth Quarter and Full- Year 2023 Product Revenue and Provides Business Update Preliminary Fourth Quarter and Full-Year 2023 Product Revenues of $46.8 million and $156.4 million, respectively 2024 Product Reve Exhibit 99.1 Cerus Corporation Announces Preliminary Fourth Quarter and Full- Year 2023 Product Revenue and Provides Business Update Preliminary Fourth Quarter and Full-Year 2023 Product Revenues of $46.8 million and $156.4 million, respectively 2024 Product Revenues expected to be between $172-$175 million, reflecting 10%-12% growth year over year January 8, 2024, CONCORD, Calif.—(BUSINESS WIRE)—
January 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 4, 2024 CERUS CORPORATION ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 4, 2024 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
January 5, 2024	EX-3.1	Amended and Restated Bylaws of Cerus Corporation EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CERUS CORPORATION (A DELAWARE CORPORATION) TABLE OF CONTENTS ARTICLE I. OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II. CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III. STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meeting 1 Section 6. Special Meetings 8 Section 7. Notice of Meeti
November 13, 2023	SC 13G/A	CERS / Cerus Corp. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.
November 13, 2023	CORRESP	CERUS CORPORATION 1220 Concord Ave., Suite 600 Concord, California 94520 (925) 288-6000 CERUS CORPORATION 1220 Concord Ave., Suite 600 Concord, California 94520 (925) 288-6000 November 13, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Re: Cerus Corporation Registration Statement on Form S-3 Filed November 2, 2023 File No. 333-275284 Ladies and Gentlemen: I
November 2, 2023	S-8	As filed with the Securities and Exchange Commission on November 2, 2023 As filed with the Securities and Exchange Commission on November 2, 2023 Registration No.
November 2, 2023	S-3	As filed with the Securities and Exchange Commission on November 2, 2023 Table of Contents As filed with the Securities and Exchange Commission on November 2, 2023 Registration No.
November 2, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Cerus Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Amended and Restated 2008 Equity Incentive Plan Common Stock, par value $0.
November 2, 2023	EX-4.3	Form of Indenture, between Registrant and one or more trustees to be named. Exhibit 4.3 CERUS CORPORATION, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities Table of Contents Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Section
November 2, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2023 CERUS CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission Fil
November 2, 2023	EX-4.6	Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 CERUS CORPORATION AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF CERUS CORPORATION FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CERUS CORPORATION, a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the l
November 2, 2023	EX-1.4	Amendment No. 2 to the Controlled Equity OfferingSM Sales Agreement, dated November 2, 2023, by and among Cerus Corporation, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated Exhibit 1.4 AMENDMENT NO. 2 TO CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT November 2, 2023 Cantor Fitzgerald & Co. 110 E. 59th St., 6th Floor New York, NY 10022 Stifel, Nicolaus & Company, Incorporated 787 7th Avenue, 11th Floor New York, NY 10019 Ladies and Gentlemen: Cerus Corporation (the “Company”), Cantor Fitzgerald & Co. (“Cantor”) and Stifel, Nicolaus & Company, Incorporated (“Stifel”, ea
November 2, 2023	EX-4.5	Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.5 CERUS CORPORATION AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF CERUS CORPORATION FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CERUS CORPORATION, a Delaware corporation (the “Company”) and [•], a [corporation] [national banking association] organized and existing under the laws of [•]
November 2, 2023	EX-4.7	Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.7 CERUS CORPORATION AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF CERUS CORPORATION FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CERUS CORPORATION, a Delaware corporation (the “Company”) and [•], a [corporation] [national banking association] organized and existing under the la
November 2, 2023	EX-10.1	Amended and Restated 2008 Equity Incentive Plan, effective June 7, 2023. Exhibit 10.1 Cerus Corporation Amended and Restated 2008 Equity Incentive Plan APPROVED BY THE BOARD OF DIRECTORS ON: APRIL 19, 2017 APPROVED BY STOCKHOLDERS ON: JUNE 7, 2017 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS ON: APRIL 19, 2019 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS ON: MAY 23, 2019 APPROVED BY STOCKHOLDERS ON: JUNE 5, 2019 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS ON: AP
November 2, 2023	EX-99.1	Cerus Corporation Announces Third Quarter 2023 Financial Results Exhibit 99.1 Cerus Corporation Announces Third Quarter 2023 Financial Results CONCORD, CA, November 2, 2023 - Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2023. Recent highlights include: • Third quarter 2023 total revenue of $47.3 million was comprised of total product revenue of $39.8 million and government contract revenue of $7.5
November 2, 2023	EX-FILING FEES	Filing fee table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) CERUS CORPORATION (Exact name of Registrant as specified in its charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee(3) Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0.
November 2, 2023	EX-10.2	Amendment No. 1 to Amended and Restated Credit, Security and Guaranty Agreement (Term Loan), dated September 1, 2023, by and among Cerus Corporation, the lenders party thereto and MidCap Financial Trust. Exhibit 10.2 Execution Version AMENDMENT NO. 1 TO AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) This AMENDMENT NO. 1 TO AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) (this “Agreement”) is made as of the 1st day of September, 2023, by and among CERUS CORPORATION, a Delaware corporation (“Borrower”), MIDCAP FINANCIAL TRUST, a Delaware statutory t
November 2, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CERUS
August 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CERUS CORP
August 2, 2023	EX-99.1	Cerus Corporation Announces Second Quarter 2023 Financial Results Exhibit 99.1 Cerus Corporation Announces Second Quarter 2023 Financial Results CONCORD, CA, August 2, 2023 - Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2023. Recent highlights include: • Second quarter 2023 total revenue of $47.7 million was comprised of total product revenue of $38.9 million and government contract revenue of $8.9 mill
August 2, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 02, 2023 CERUS CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File
June 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 07, 2023 CERUS CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Nu
May 31, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Cerus Corporation (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Cerus Corporation (Exact name of registrant as specified in its charter) Delaware 000-21937 68-0262011 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 1220 Concord Ave, Suite 600 Concord, California 94520 (Address of
May 24, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant  Filed by a party other than the Registrant  Check the appropriate box:  Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  Defini
May 4, 2023	EX-10	Amended and Restated Credit, Security and Guaranty Agreement (Revolving Loan), dated March 31, 2023, by and among Cerus Corporation, the lenders party thereto and MidCap Financial IV Trust. Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE CERUS CORPORATION HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CERUS CORPORATION IF PUBLICLY DISCLOSED. Execution Version Exhibit 10.3 AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN) dated as of March
May 4, 2023	EX-10	Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.4 Cerus Corporation Amended and Restated Non-Employee Director Compensation Policy Effective: January 1, 2012 Amended by Compensation Committee: February 13, 2014 Approved by Board of Directors: February 14, 2014 Amended by Board of Directors: April 19, 2017 Amended by Board of Directors: March 2, 2018 Amended by Board of Directors: March 27, 2020 Amended by Board of Directors: February
May 4, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported)May 04, 2023 CERUS CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
May 4, 2023	EX-10	Amended and Restated Credit, Security and Guaranty Agreement (Term Loan), dated March 31, 2023, by and among Cerus Corporation, the lenders party thereto and MidCap Financial Trust. Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE CERUS CORPORATION HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CERUS CORPORATION IF PUBLICLY DISCLOSED. Execution Version Exhibit 10.2 AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) dated as of March 31,
May 4, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CERUS C
May 4, 2023	EX-99	Cerus Corporation Announces First Quarter 2023 Financial Results Reiterating Full-Year 2023 Product Revenue Guidance Range of $165-170 Million Exhibit 99.1 Cerus Corporation Announces First Quarter 2023 Financial Results Reiterating Full-Year 2023 Product Revenue Guidance Range of $165-170 Million CONCORD, CA, May 4, 2023 - Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2023. Recent highlights include: • First quarter 2023 total revenue of $38.5 million was comprised of (in thousa
April 28, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte
April 5, 2023	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2023 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
March 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2023 CERUS CORPORATION (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2023 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
March 1, 2023	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-21937 CERUS CORPORATION (Exact n
March 1, 2023	POSASR	Power of Attorney (see signature page to Post Effective Amendment No. 1 to this registration statement). POSASR Table of Contents As filed with the Securities and Exchange Commission on March 1, 2023 Registration No.
March 1, 2023	EX-21	List of Registrant’s subsidiaries. Exhibit 21.1 Cerus Corporation Subsidiaries of the Registrant Legal Name Jurisdiction of Formation Cerus Europe B.V. Netherlands
March 1, 2023	EX-1.3	Amendment No. 1 to Controlled Equity OfferingSM Sales Agreement, dated March 1, 2023, by and among Cerus Corporation, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated. EX-1.3 2 d470086dex13.htm EX-1.3 Exhibit 1.3 AMENDMENT NO. 1 TO CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT March 1, 2023 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Stifel, Nicolaus & Company, Incorporated 787 7th Avenue, 11th Floor New York, NY 10019 Ladies and Gentlemen: Cerus Corporation (the “Company”), Cantor Fitzgerald & Co. (“Cantor”) and Stifel, Nicolaus & Company, Incorpo
March 1, 2023	EX-FILING FEES	Filing fee table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Cerus Corporation (Exact name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common Stock, $0.
March 1, 2023	POS AM	Risk Factors POS AM Table of Contents As filed with the Securities and Exchange Commission on March 1, 2023 Registration No.
February 28, 2023	EX-99.1	Cerus Corporation Announces Record Fourth Quarter and Full-Year 2022 Financial Results Strong Revenue Growth Driven by Sales in North America Product Revenue of $44.0 Million Grew 10% YoY in the Fourth Quarter Reiterating Full-Year 2023 Product Reven EX-99.1 Exhibit 99.1 Cerus Corporation Announces Record Fourth Quarter and Full-Year 2022 Financial Results Strong Revenue Growth Driven by Sales in North America Product Revenue of $44.0 Million Grew 10% YoY in the Fourth Quarter Reiterating Full-Year 2023 Product Revenue Guidance Range of $165-170 Million CONCORD, CA, February 28, 2023 - Cerus Corporation (Nasdaq: CERS) today announced financial
February 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2023 CERUS CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2023 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
February 14, 2023	SC 13G/A	CERS / Cerus Corporation / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SC 13G/A 1 tm234999d29sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 8)* Cerus Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 157085101 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate
February 10, 2023	SC 13G/A	CERS / Cerus Corporation / Nikko Asset Management Americas, Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Cerus Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 157085101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
February 10, 2023	SC 13G/A	CERS / Cerus Corporation / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
February 10, 2023	SC 13G/A	CERS / Cerus Corporation / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
February 9, 2023	SC 13G/A	CERS / Cerus Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Cerus Corp. Title of Class of Securities: Common Stock CUSIP Number: 157085101 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13
February 3, 2023	SC 13G/A	CERS / Cerus Corporation / Sumitomo Mitsui Trust Holdings, Inc. - AMENDMENT NO. 3 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Cerus Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 157085101 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul
January 9, 2023	EX-99.1	Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2022 Product Revenue and Provides Business Update Preliminary Fourth Quarter and Full-Year 2022 Product Revenues of $44.0 million and $162.0 million reflecting year-over-year growth EX-99.1 Exhibit 99.1 Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2022 Product Revenue and Provides Business Update Preliminary Fourth Quarter and Full-Year 2022 Product Revenues of $44.0 million and $162.0 million reflecting year-over-year growth of 10% and 24%, respectively January 9, 2023, CONCORD, Calif.—(BUSINESS WIRE)—Cerus Corporation (Nasdaq: CERS) today announced p
January 9, 2023	SC 13G/A	CERS / Cerus Corporation / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* Cerus Corp (Name of Issuer) COM (Title of Class of Securities) 157085101 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X
January 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 CERUS CORPORATION ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
November 3, 2022	EX-99.1	Cerus Corporation Announces Third Quarter Financial Results Total Revenue of $46.3 Million Grew 10% YoY in the Third Quarter Product Revenue of $39.6 Million Grew 10% YoY in the Third Quarter despite 6% FX headwind Exhibit 99.1 Cerus Corporation Announces Third Quarter Financial Results Total Revenue of $46.3 Million Grew 10% YoY in the Third Quarter Product Revenue of $39.6 Million Grew 10% YoY in the Third Quarter despite 6% FX headwind CONCORD, CA, November 3, 2022 - Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2022. Recent developments and h
November 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CER
November 3, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2022 CERUS CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2022 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
October 24, 2022	CORRESP	* * * * * October 24, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
August 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2022 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
August 4, 2022	EX-10.2	Second Amended and Restated Manufacturing and Supply Agreement, by and between Cerus Corporation and Fresenius Kabi AG, Fenwal France SAS, and Fenwal International, Inc, effective as of January 1, 2022. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
August 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CERUS CO
August 4, 2022	S-8	Power of Attorney is contained on the signature pages. As filed with the Securities and Exchange Commission on August 4, 2022 Registration No.
August 4, 2022	EX-FILING FEES	Filing Fee Table. EX-FILING FEES 4 d380264dexfilingfees.htm EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Cerus Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Pri
August 4, 2022	EX-10.1	Amended and Restated Non-Employee Director Compensation Policy, effective February 17, 2022. Exhibit 10.1 Cerus Corporation Amended and Restated Non-Employee Director Compensation Policy Effective: January 1, 2012 Amended by Compensation Committee: February 13, 2014 Approved by Board of Directors: February 14, 2014 Amended by Board of Directors: April 19, 2017 Amended by Board of Directors: March 2, 2018 Amended by Board of Directors: March 27, 2020 Amended by Board of Directors: February
August 4, 2022	EX-99.1	Cerus Corporation Announces Another Record Quarter and Reiterates Full Year 2022 Product Revenue Guidance Range Second Quarter 2022 is Highest Product Revenue in Company History Total Revenue of $47.6 Million Grew 26% YoY in the Second Quarter Produc Exhibit 99.1 Cerus Corporation Announces Another Record Quarter and Reiterates Full Year 2022 Product Revenue Guidance Range Second Quarter 2022 is Highest Product Revenue in Company History Total Revenue of $47.6 Million Grew 26% YoY in the Second Quarter Product Revenue of $41.0 Million Grew 30% YoY in the Second Quarter Reiterating Full-Year 2022 Product Revenue Guidance Range of $160-165 Milli
August 4, 2022	EX-10.3	Amended and Restated 2008 Equity Incentive Plan. Exhibit 10.3 CERUS CORPORATION AMENDED AND RESTATED 2008 EQUITY INCENTIVE PLAN APPROVED BY THE BOARD OF DIRECTORS ON: APRIL 19, 2017 APPROVED BY STOCKHOLDERS ON: JUNE 7, 2017 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS ON: APRIL 19, 2019 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS ON: MAY 23, 2019 APPROVED BY STOCKHOLDERS ON: JUNE 5, 2019 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS ON: AP
July 5, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2022 Cerus Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Nu
July 5, 2022	EX-99.1	Cerus Corporation Announces Appointment of Hua Shan, MD, PhD to Board of Directors Exhibit 99.1 Cerus Corporation Announces Appointment of Hua Shan, MD, PhD to Board of Directors CONCORD, CA, July 5, 2022 - Cerus Corporation (Nasdaq: CERS) today announced the appointment of Hua Shan, MD, PhD, Professor of Pathology and Medical Director, Transfusion Medicine Service at Stanford Medical Center to its Board of Directors. ?We are pleased to welcome Dr. Shan to Cerus? Board of Direct
June 2, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 Cerus Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Num
May 31, 2022	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Cerus Corporation (Exact name of registrant as specified in its charter) Delaware 000-21937 68-0262011 (State or other jurisdiction of incor UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Cerus Corporation (Exact name of registrant as specified in its charter) Delaware 000-21937 68-0262011 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 1220 Concord Ave, Suite 600 Concord, California 94520 (Address of
May 31, 2022	EX-1.01	Conflict Minerals Report of Cerus Corporation EX-1.01 2 d361221dex101.htm EX-1.01 Exhibit 1.01 Cerus Corporation Conflict Minerals Report For the reporting period from January 1, 2021 to December 31, 2021 This Conflict Minerals Report (the “Report”) of Cerus Corporation (“Cerus”) has been prepared pursuant to Rule 13p-1 and Form SD (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January
May 5, 2022	EX-10.1	2021 and 2022 Executive Officer Compensation Arrangements. Exhibit 10.1 2021 and 2022 Executive Officer Compensation Arrangements The compensation for the executive officers of Cerus Corporation regarding annual base salaries and target bonus percentages were as follows: Name 2021 Annual Base Salary as of March 1 2021 Targeted Bonus (paid in 2022) 2022 Annual Base Salary as of March 1 2022 Targeted Bonus (to be paid in 2023) William M. Greenman President
May 5, 2022	EX-99.1	Cerus Corporation Announces First Quarter 2022 Financial Results and Increases Full Year 2022 Product Revenue Guidance Range Growth From All Geographic Regions with Results Driven by INTERCEPT Platelet Uptake in the U.S. Total Revenue of $43.0 Millio Exhibit 99.1 Cerus Corporation Announces First Quarter 2022 Financial Results and Increases Full Year 2022 Product Revenue Guidance Range Growth From All Geographic Regions with Results Driven by INTERCEPT Platelet Uptake in the U.S. Total Revenue of $43.0 Million Grew 46% YoY in the First Quarter Product Revenue of $37.4 Million Grew 60% YoY in the First Quarter Increasing Full-Year 2022 Product
May 5, 2022	10-Q	Quarterly Report on Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CERUS C
May 5, 2022	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2022 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
May 5, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2022 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
April 22, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 22, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 d266263ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Us
February 22, 2022	EX-10.6	Second Amendment to Supply and Manufacturing Agreement by and between Cerus Corporation and Porex Corporation, dated December 21, 2021. [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
February 22, 2022	EX-10.20	Amendment No. 2 to Credit, Security and Guaranty Agreement (Revolving Loan), dated December 23, 2021, by and among Cerus Corporation, the lenders party thereto and MidCap Financial Trust. [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
February 22, 2022	EX-21.1	List of Registrant’s subsidiaries. Exhibit 21.1 Cerus Corporation Subsidiaries of the Registrant Legal Name Jurisdiction of Formation Cerus Europe B.V. Netherlands
February 22, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 22, 2022 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
February 22, 2022	EX-99.1	Cerus Corporation Announces Record Fourth Quarter and Full-Year 2021 Financial Results Strong Revenue Growth Driven by U.S. Adoption of INTERCEPT Platelets Total Revenue of $50.1 Million Grew 49% in the Fourth Quarter Product Revenue of $39.9 Million Exhibit 99.1 Cerus Corporation Announces Record Fourth Quarter and Full-Year 2021 Financial Results Strong Revenue Growth Driven by U.S. Adoption of INTERCEPT Platelets Total Revenue of $50.1 Million Grew 49% in the Fourth Quarter Product Revenue of $39.9 Million Grew 41% in the Fourth Quarter Reiterating Full-Year 2022 Product Revenue Guidance Range of $157-164 Million CONCORD, CA, February 22, 2
February 22, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-21937 CERUS CORPORATION (Exact n
February 14, 2022	SC 13G/A	CERS / Cerus Corporation / Nikko Asset Management Americas, Inc. - SC13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cerus Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 157085101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
February 10, 2022	SC 13G/A	CERS / Cerus Corporation / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* Cerus Corp (Name of Issuer) COM (Title of Class of Securities) 157085101 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X
February 9, 2022	SC 13G/A	CERS / Cerus Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Cerus Corp. Title of Class of Securities: Common Stock CUSIP Number: 157085101 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13
February 9, 2022	SC 13G/A	CERS / Cerus Corporation / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
February 4, 2022	SC 13G/A	CERS / Cerus Corporation / Sumitomo Mitsui Trust Holdings, Inc. - AMENDMENT NO. 2 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cerus Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 157085101 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul
January 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2022 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
January 10, 2022	EX-99.1	Cerus Corporation Announces Record Preliminary Fourth Quarter and Full-Year 2021 Product Revenue and Provides Business Update Preliminary Q4:21 and Full-Year 2021 Product Revenues of $39.9 million and $130.9 million reflects year-over-year growth of Exhibit 99.1 Cerus Corporation Announces Record Preliminary Fourth Quarter and Full-Year 2021 Product Revenue and Provides Business Update Preliminary Q4:21 and Full-Year 2021 Product Revenues of $39.9 million and $130.9 million reflects year-over-year growth of 41% and 42%, respectively 2022 Product Revenues expected to be between $157-164 million, reflecting 20%-25% growth versus 2021 Expanding
December 23, 2021	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 21, 2021 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
November 2, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CER
November 2, 2021	EX-99.1	Cerus Corporation Announces Record Third Quarter 2021 Financial Results and Raises Full-Year Product Revenue Guidance Accelerating Revenue Growth Driven by U.S. Adoption of INTERCEPT Platelets Total Revenue of $42.1 Million Grew 44% in the Third Quar Exhibit 99.1 Cerus Corporation Announces Record Third Quarter 2021 Financial Results and Raises Full-Year Product Revenue Guidance Accelerating Revenue Growth Driven by U.S. Adoption of INTERCEPT Platelets Total Revenue of $42.1 Million Grew 44% in the Third Quarter Product Revenue of $36.1 Million Grew 53% in the Third Quarter Full-Year 2021 Product Revenue Guidance Range Raised to $127-129 Milli
November 2, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2021 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
November 2, 2021	EX-10.1	Amendment No. 2 to Credit, Security and Guaranty Agreement (Term Loan), dated September 30, 2021, by and among Cerus Corporation, the lenders party thereto and MidCap Financial Trust. Exhibit 10.1 Execution Version AMENDMENT NO. 2 TO CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) This AMENDMENT NO. 2 TO CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) (this ?Agreement?) is made as of the 30th day of September, 2021, by and among CERUS CORPORATION, a Delaware corporation (?Borrower?), MIDCAP FINANCIAL TRUST, a Delaware statutory trust, as Agent (in such capacity, togethe
August 3, 2021	10-Q	Quarterly Report on Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CERUS CO
August 3, 2021	EX-99.1	Cerus Corporation Announces Record Second Quarter 2021 Financial Results and Raises Full Year Product Revenue Guidance Highest Quarterly Total and Product Revenue in Company History Total Revenue of $37.8 Million Grew 41% in Second Quarter Product Re Exhibit 99.1 Cerus Corporation Announces Record Second Quarter 2021 Financial Results and Raises Full Year Product Revenue Guidance Highest Quarterly Total and Product Revenue in Company History Total Revenue of $37.8 Million Grew 41% in Second Quarter Product Revenue of $31.5 Million Led by 128% Growth in North America as INTERCEPT Platelet Sales Ramped in the U.S. Full-Year 2021 Product Revenue
August 3, 2021	S-8	As filed with the Securities and Exchange Commission on August 3, 2021 S-8 1 d108724ds8.htm S-8 As filed with the Securities and Exchange Commission on August 3, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CERUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 68-0262011 (State of Incorporation) (I.R.S. Employer Identifica
August 3, 2021	EX-10.1	Amended and Restated 2008 Equity Incentive Plan, effective June 2, 2021. Exhibit 10.1 CERUS CORPORATION AMENDED AND RESTATED 2008 EQUITY INCENTIVE PLAN APPROVED BY THE BOARD OF DIRECTORS ON: APRIL 19, 2017 APPROVED BY STOCKHOLDERS ON: JUNE 7, 2017 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS ON: APRIL 19, 2019 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS ON: MAY 23, 2019 APPROVED BY STOCKHOLDERS ON: JUNE 5, 2019 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS ON: AP
August 3, 2021	EX-10.2	Amended and Restated Non-Employee Director Compensation Policy, effective February 22, 2021. Exhibit 10.2 Cerus Corporation Amended and Restated Non-Employee Director Compensation Policy Effective: January 1, 2012 Amended by Compensation Committee: February 13, 2014 Approved by Board of Directors: February 14, 2014 Amended by Board of Directors: April 19, 2017 Amended by Board of Directors: March 2, 2018 Amended by Board of Directors: March 27, 2020 Amended by Board of Directors: February
August 3, 2021	EX-3.4	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cerus Corporation. Exhibit 3.4 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CERUS CORPORATION A Delaware Corporation Cerus Corporation, a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify as follows: FIRST: The name of the Corporation is Cerus Corporation. SECOND: The date of filing the original Certificate of In
August 3, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 3, 2021 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
June 7, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 Cerus Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Num
May 28, 2021	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Cerus Corporation (Exact name of registrant as specified in its charter) Delaware 000-21937 68-0262011 (State or other jurisdiction of incor UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Cerus Corporation (Exact name of registrant as specified in its charter) Delaware 000-21937 68-0262011 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 1220 Concord Ave, Suite 600 Concord, California 94520 (Address of
May 28, 2021	EX-1.01	Conflict Minerals Report of Cerus Corporation Exhibit 1.01 Cerus Corporation Conflict Minerals Report For the reporting period from January 1, 2020 to December 31, 2020 This Conflict Minerals Report (the “Report”) of Cerus Corporation (“Cerus”) has been prepared pursuant to Rule 13p-1 and Form SD (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January 1, 2020 to December 31, 2020. The R
May 4, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2021 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
May 4, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CERUS C
May 4, 2021	EX-99.1	Cerus Corporation Announces First Quarter 2021 Financial Results and Raises Full Year Product Revenue Guidance EX-99.1 2 d181005dex991.htm EX-99.1 Exhibit 99.1 Cerus Corporation Announces First Quarter 2021 Financial Results and Raises Full Year Product Revenue Guidance CONCORD, CA, May 4, 2021 - Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2021. Recent developments and highlights include: • First quarter 2021 total revenue of $29.6 million, refle
May 4, 2021	EX-10.2	Letter Agreement, by and between Cerus Corporation and Porex Corporation, dated January 6, 2021. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE CERUS CORPORATION HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CERUS CORPORATION IF PUBLICLY DISCLOSED Exhibit 10.
May 4, 2021	EX-10.1	2020 and 2021 Executive Officer Compensation Arrangements. Exhibit 10.1 2020 and 2021 Executive Officer Compensation Arrangements The compensation for the executive officers of Cerus Corporation regarding annual base salaries and target bonus percentages were as follows: Name 2020 Annual Base Salary as of March 1 2020 Targeted Bonus (paid in 2021) 2021 Annual Base Salary as of March 1 2021 Targeted Bonus (to be paid in 2022) William M. Greenman President
April 23, 2021	DEFA14A	- DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 23, 2021	DEF 14A	definitive proxy statement Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 2, 2021	PRE 14A	- PRE 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 31, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 26, 2021 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
February 25, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-21937 CERUS CORPORATION (Exact n
February 25, 2021	EX-21.1	List of Registrant’s subsidiaries. Exhibit 21.1 Cerus Corporation Subsidiaries of the Registrant Legal Name Jurisdiction of Formation Cerus Europe B.V. Netherlands
February 25, 2021	EX-10.2	First Amendment to Amended and Restated Supply Agreement, dated December 1, 2020, by and between Cerus Corporation and Purolite Corporation. EX-10.2 2 cers-ex102179.htm EX-10.2 Exhibit 10.2 FIRST AMENDMENT TO AMENDED AND RESTATED SUPPLY AGREEMENT This first amendment to amended and restated SUPPLY agreement (this “Amendment”), dated as of December 1, 2020 (the “Amendment Date”), is by and between Cerus Corporation (“Cerus”) and Purolite Corporation (“Purolite”). Cerus and Purolite are each hereinafter sometimes referred to as a “Party”
February 25, 2021	EX-99.1	Cerus Corporation Announces Record Fourth Quarter and Full Year 2020 Financial Results EX-99.1 Exhibit 99.1 Cerus Corporation Announces Record Fourth Quarter and Full Year 2020 Financial Results CONCORD, CA, February 25, 2021—Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and year ended December 31, 2020. Recent developments and highlights include: • Record total fourth quarter and full year 2020 revenues of $33.6 million and $114.2 million
February 25, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2021 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
February 25, 2021	EX-10.14	Amendment No. 1 to Credit, Security and Guaranty Agreement (Term Loan), dated December 31, 2020, by and among Cerus Corporation, the lenders party thereto and MidCap Financial Trust. Exhibit 10.14 Execution Version amendment No. 1 to CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) This AMENDMENT NO. 1 TO CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) (this ?Agreement?) is made as of 31st day of December, 2020, by and among CERUS CORPORATION, a Delaware corporation (?Borrower?), MidCap Financial Trust, a Delaware statutory trust, as Agent (in such capacity, together wi
February 25, 2021	EX-10.8	Amendment #2 to the Amended and Restated Manufacturing and Supply Agreement, by and between Cerus Corporation and Fresenius Kabi Deutschland GmbH, dated December 23, 2020 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE CERUS CORPORATION HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CERUS CORPORATION IF PUBLICLY DISCLOSED.
February 25, 2021	EX-10.16	Amendment No. 1 to Credit, Security and Guaranty Agreement (Revolving Loan), dated December 31, 2020, by and among Cerus Corporation, the lenders party thereto and MidCap Financial Trust. EX-10.16 5 cers-ex1016182.htm EX-10.16 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE CERUS CORPORATION HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CERUS CORPORATION IF PUBLICLY DISCLOSED. Exhibit 10.16 Execution Version amendment No. 1 to CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVIN
February 16, 2021	SC 13G/A	SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 7)* Cerus Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) (CUSIP Number SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* CERUS CORPORATION (Name of Issuer) Common stock (Title of Class of Securities) (CUSIP Number) December 31, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
February 12, 2021	SC 13G/A	SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6 )* Cerus Corporation (Name of Issuer) (Title of Class of Securities) (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.
February 11, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SC 13G/A 1 brhc10020165sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cerus Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 157085101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Cerus Corp. Title of Class of Securities: Common Stock CUSIP Number: 157085101 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13
February 5, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cerus Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 157085101 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule
January 29, 2021	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2021 Cerus Corporation (Exact name of registrant as specified in its charter) Delaware 000-21937 68-0262011 (State or other jurisdiction of incorporation) (Commission File
January 11, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 11, 2021 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
January 11, 2021	EX-99.1	Cerus Corporation Announces Preliminary Fourth Quarter and Full Year 2020 Product Revenue Company also provides 2021 product revenue guidance EX-99.1 2 d33525dex991.htm EX-99.1 Exhibit 99.1 Cerus Corporation Announces Preliminary Fourth Quarter and Full Year 2020 Product Revenue Company also provides 2021 product revenue guidance CONCORD, CA, January 11, 2021 - Cerus Corporation (Nasdaq: CERS) announced today preliminary product revenue for the fourth quarter and full year 2020 and provided 2021 product revenue guidance. Cerus’ unaudite
January 6, 2021	8-K	Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2020 Cerus Corporation (Exact name of registrant as specified in its charter) Delaware 000-21937 68-0262011 (State or other jurisdiction of incorporation) (Commission Fil
December 11, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2020 Cerus Corporation (Exact name of registrant as specified in its charter) Delaware 000-21937 68-0262011 (State or other jurisdiction of incorporation) (Commission Fil
December 11, 2020	EX-99.1	RISK FACTORS EX-99.1 Exhibit 99.1 As used in this Exhibit 99.1, “Cerus,” “Cerus Corporation,” the “Company,” “we,” “us” and “our” refer to Cerus Corporation, a Delaware corporation, and its wholly-owned subsidiary, Cerus Europe B.V. Cerus, INTERCEPT and INTERCEPT Blood System are U.S. registered trademarks of Cerus Corporation. All other trademarks, service marks and trade names included in this Exhibit 99.1 a
December 11, 2020	EX-4.3	Form of Indenture, between Registrant and one or more trustees to be named. EXHIBIT 4.3 CERUS CORPORATION Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 6 Section 2.01 Designation and Terms of Securities 6 Section 2.02 Form of Securities and Trustee’s Certificate 8 Section 2.
December 11, 2020	424B5	CALCULATION OF REGISTRATION FEE TITLE OF EACH CLASS OF SECURITIES TO BE REGISTERED PROPOSED MAXIMUM AGGREGATE OFFERING PRICE(1) AMOUNT OF REGISTRATION FEE(2) Common Stock, $0.001 par value per share $100,000,000 $10,910.00 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-251302 CALCULATION OF REGISTRATION FEE TITLE OF EACH CLASS OF SECURITIES TO BE REGISTERED PROPOSED MAXIMUM AGGREGATE OFFERING PRICE(1) AMOUNT OF REGISTRATION FEE(2) Common Stock, $0.001 par value per share $100,000,000 $10,910.00 (1) Calculated pursuant to Rule 457(o) under the Securities Act of 1933, as amended. (2) The
December 11, 2020	EX-4.7	Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.7 EXHIBIT 4.7 CERUS CORPORATION AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF CERUS CORPORATION FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between CERUS CORPORATION , a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing und
December 11, 2020	S-3ASR	- S-3ASR S-3ASR Table of Contents As filed with the Securities and Exchange Commission on December 11, 2020 Registration No.
December 11, 2020	EX-1.1	Controlled Equity OfferingSM Sales Agreement, dated December 11, 2020, by and among Cerus Corporation, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated EX-1.1 2 d11427dex11.htm EX-1.1 Exhibit 1.1 Execution Version CERUS CORPORATION Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement December 11, 2020 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Stifel, Nicolaus & Company, Incorporated 787 7th Avenue, 11th Floor New York, NY 10019 Ladies and Gentlemen: Cerus Corporation, a Delaware corpora
December 11, 2020	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2020 Cerus Corporation (Exact name of registrant as specified in its charter) Delaware 000-21937 68-0262011 (State or other jurisdiction of incorporation) (Commission Fil
December 11, 2020	EX-4.6	Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.6 EXHIBIT 4.6 CERUS CORPORATION AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF CERUS CORPORATION FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between CERUS CORPORATION , a Delaware corporation (the “ Company ”), and [●], a [corporation] [national banking association] organized and existing u
December 11, 2020	EX-4.5	Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.5 EXHIBIT 4.5 CERUS CORPORATION AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF CERUS CORPORATION FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between CERUS CORPORATION, a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the law
October 29, 2020	EX-99.1	Cerus Corporation Announces Record Third Quarter 2020 Results EX-99.1 2 d92850dex991.htm EX-99.1 Exhibit 99.1 Cerus Corporation Announces Record Third Quarter 2020 Results CONCORD, CA, Oct 29, 2020 - Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2020. Recent developments and highlights include: • Q3 2020 Total Revenue of $29.2 million - driven by significant year-over-year platelet kit sales grow
October 29, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CER
October 29, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2020 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
October 9, 2020	SC 13G/A	CERS / Cerus Corp. / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
August 5, 2020	EX-10.4	Amended and Restated 2008 Equity Incentive Plan, effective June 3, 2020 Exhibit 10.4 CERUS CORPORATION AMENDED AND RESTATED 2008 EQUITY INCENTIVE PLAN APPROVED BY THE BOARD OF DIRECTORS ON: APRIL 19, 2017 APPROVED BY STOCKHOLDERS ON: JUNE 7, 2017 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS ON: APRIL 19, 2019 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS ON: MAY 23, 2019 APPROVED BY STOCKHOLDERS ON: JUNE 5, 2019 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS ON: AP
August 5, 2020	EX-10.3	Amended and Restated 1996 Employee Stock Purchase Plan, effective June 3, 2020 EX-10.3 4 cers-ex103141.htm EX-10.3 Exhibit 10.3 CERUS CORPORATION AMENDED AND RESTATED EMPLOYEE STOCK PURCHASE PLAN 1. PURPOSE. (a) The purpose of the Employee Stock Purchase Plan (the “Plan”) is to provide a means by which employees of Cerus Corporation, a California corporation (the “Company”), and its Affiliates, as defined in subparagraph 1(b), which are designated as provided in subparagraph
August 5, 2020	S-8	- S-8 S-8 As filed with the Securities and Exchange Commission on August 4, 2020 Registration No.
August 5, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CERUS CO
August 5, 2020	EX-10.2	The Executive Nonqualified Excess Plan Adoption Agreement, dated May 21, 2020 EX-10.2 3 cers-ex102140.htm EX-10.2 Exhibit 10.2 THE EXECUTIVE NONQUALIFIED EXCESS PLAN ADOPTION AGREEMENT THIS AGREEMENT is the adoption by Cerus Corporation (the "Company") of the Executive Nonqualified Excess Plan ("Plan"). W I T N E S S E T H: WHEREAS, the Company desires to adopt the Plan as an unfunded, nonqualified deferred compensation plan; and WHEREAS, the provisions of the Plan are inte
August 5, 2020	EX-10.1	Nonqualified Plan Service and Expense Agreement, by and between Cerus Corporation and Principal Life Insurance Company, dated May 21, 2020 EX-10.1 2 cers-ex101139.htm EX-10.1 [ ** ] = CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BECAUSE THE OMITTED PORTIONS ARE BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED Exhibit 10.1 Nonqualified Plan Service and Expense Agreement This Agreement is made by and between the undersigned Plan Representative (“you”, “your”) and the undersigned member company of
August 4, 2020	EX-99.1	Cerus Corporation Announces Record Second Quarter 2020 Results EX-99.1 2 d65460dex991.htm EX-99.1 Exhibit 99.1 Cerus Corporation Announces Record Second Quarter 2020 Results CONCORD, CA, Aug 4, 2020 - Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2020. Recent developments and highlights include: • Q2 2020 Total Revenue of $26.8 million - driven by robust year-over-year platelet kit sales growth in the
August 4, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2020 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
June 8, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2020 Cerus Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdition of Incorporation) (Commission File Numb
May 29, 2020	EX-1.01	Cerus Corporation Conflict Minerals Report For the reporting period from January 1, 2019 to December 31, 2019 EX-1.01 2 d918655dex101.htm EX-1.01 Exhibit 1.01 Cerus Corporation Conflict Minerals Report For the reporting period from January 1, 2019 to December 31, 2019 This Conflict Minerals Report (the “Report”) of Cerus Corporation (“Cerus”) has been prepared pursuant to Rule 13p-1 and Form SD (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January
May 29, 2020	SD	- SD SD 1 d918655dsd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Cerus Corporation (Exact name of registrant as specified in its charter) Delaware 000-21937 68-0262011 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 1220 Concord Ave, Suite 600 Concord, Calif
May 28, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2020 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
May 5, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2020 CERUS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 000-21937 68-0262011 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
May 5, 2020	EX-99.1	Cerus Corporation Announces First Quarter 2020 Results EX-99.1 2 d927626dex991.htm EX-99.1 Exhibit 99.1 Cerus Corporation Announces First Quarter 2020 Results CONCORD, CA, May 5, 2020 - Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2020. Recent developments and highlights include: • Total first quarter 2020 revenue of $24.6 million • Quarterly product revenue of $18.6 million, a 6% increase co
May 5, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CERUS C
May 5, 2020	EX-10.1	2019 and 2020 Executive Officer Compensation Arrangements Exhibit 10.1 2019 and 2020 Executive Officer Compensation Arrangements The compensation for the executive officers of Cerus Corporation regarding annual base salaries and target bonus percentages were as follows: Name 2019 Annual Base Salary as of March 1 2019 Targeted Bonus (paid in 2020) 2020 Annual Base Salary as of March 1 2020 Targeted Bonus (to be paid in 2021) William M. Greenman President
May 5, 2020	EX-10.3	Side Letter to Supply Agreement, dated January 14, 2020, by and between Cerus Corporation and Fresenius Kabi Deutschland GmbH. EX-10.3 4 cers-ex10376.htm EX-10.3 [***] = CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BECAUSE THE OMITTED PORTIONS ARE BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. Exhibit 10.3 14 January 2020 Via Electronic Mail Fresenius Kabi Deutschland GmbH Else-Kröner-Straße 1 61352 Bad Homburg Attention: Dr. Christian Hauer Re: Side Letter to Supply Agreement Dea
May 5, 2020	EX-10.2	Amended and Restated Non-Employee Director Compensation Policy, effective March 27, 2020 EX-10.2 3 cers-ex102170.htm EX-10.2 Exhibit 10.2 Cerus Corporation Amended and Restated Non-Employee Director Compensation Policy Effective: January 1, 2012 Amended by Compensation Committee: February 13, 2014 Approved by Board of Directors: February 14, 2014 Amended by Board of Directors: April 19, 2017 Amended by Board of Directors: March 2, 2018 Amended by Board of Directors: March 27, 2020 Eac
April 24, 2020	DEFA14A	- DEFA14A DEFA14A 1 d852621ddefa14a.htm DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement
April 24, 2020	DEF 14A	definitive proxy statement DEF 14A 1 d871374ddef14a.htm DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive
March 2, 2020	EX-99.1	Cerus Corporation Announces Strategic Organizational Changes Vivek Jayaraman promoted to Chief Operating Officer Dr. Nina Mufti promoted to VP Development and Red Blood Cell Program Leader Dr. Yasmin Singh promoted to VP Development and Platelet/Plas EX-99.1 2 d873783dex991.htm EX-99.1 Exhibit 99.1 Cerus Corporation Announces Strategic Organizational Changes Vivek Jayaraman promoted to Chief Operating Officer Dr. Nina Mufti promoted to VP Development and Red Blood Cell Program Leader Dr. Yasmin Singh promoted to VP Development and Platelet/Plasma/Therapeutics Program Leader CONCORD, CA, March 2, 2020 - Cerus Corporation (Nasdaq:CERS) today ann
March 2, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2020 Cerus Corporation (Exact name of registrant as specified in its charter) Delaware 000-21937 68-0262011 (State or other jurisdiction of incorporation) (Commission File Nu
February 21, 2020	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-21937 CERUS CORPORATION (Exact n
February 21, 2020	EX-21.1	List of Registrant’s subsidiaries. EX-21.1 3 cers-ex21116.htm EX-21.1 Exhibit 21.1 Cerus Corporation Subsidiaries of the Registrant Legal Name Jurisdiction of Formation Cerus Europe B.V. Netherlands
February 21, 2020	EX-4.2	Exhibit 4.2 EX-4.2 2 cers-ex42425.htm EX-4.2 Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK Our amended and restated certificate of incorporation, as amended, or the Restated Certificate, authorizes us to issue 225,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. The following summary description of our capital stock is based on the pro
February 20, 2020	EX-99.1	Cerus Corporation Announces Record Fourth Quarter and Full Year 2019 Financial Results EX-99.1 2 d871007dex991.htm EX-99.1 Exhibit 99.1 Cerus Corporation Announces Record Fourth Quarter and Full Year 2019 Financial Results CONCORD, CA, February 20, 2020 - Cerus Corporation (Nasdaq: CERS) today announced complete financial results for the fourth quarter and year ended December 31, 2019. Recent developments and highlights include: • Total fourth quarter revenue of $26.5 million. • Rec
February 20, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2020 Cerus Corporation (Exact name of registrant as specified in its charter) Delaware 000-21937 68-0262011 (State or other jurisdiction of incorporation) (Commission Fil
February 14, 2020	SC 13G	CERS / Cerus Corp. / ARK Investment Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
February 12, 2020	SC 13G/A	CERS / Cerus Corp. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G/A Passive Investment UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.
February 12, 2020	SC 13G	CERS / Cerus Corp. / Sumitomo Mitsui Trust Holdings, Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* Cerus Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 157085101 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul
February 12, 2020	SC 13G	CERS / Cerus Corp. / Nikko Asset Management Americas, Inc. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Cerus Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 157085101 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru
February 11, 2020	SC 13G	CERS / Cerus Corp. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Cerus Corp Title of Class of Securities: Common Stock CUSIP Number: 157085101 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c
January 30, 2020	EX-1.1	Underwriting Agreement EX-1.1 2 d856695dex11.htm EX-1.1 Exhibit 1.1 14,666,667 Shares CERUS CORPORATION Common Stock UNDERWRITING AGREEMENT January 28, 2020 BTIG, LLC 65 East 55th Street New York, New York 10022 Dear Sirs: INTRODUCTORY. Cerus Corporation, a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Agreement, to BTIG, LLC (“BTIG” or the “Underwriter,”), an aggregate of 14,666,
January 30, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2020 Cerus Corporation (Exact name of registrant as specified in its charter) Delaware 000-21937 68-0262011 (State or other jurisdiction of incorporation) (Commission File

CERS / Cerus Corporation - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings